旧金山 - Jaguar Health, Inc. (NASDAQ:JAGX)今日宣布计划推出Neonorm Dog,这是一款植物基非处方产品,旨在支持犬类正常粪便形成、肠道水合作用和肠道健康。该产品推出之际,公司正面临财务逆风,股价目前接近52周低点6.63美元,过去一年下跌98.5%。 该产品扩展了Jaguar现有的Neonorm产品系列,目前该系列包括面向断奶前马驹和小牛的Neonorm F ...

Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with ...

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS ...

Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today annou ...

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib – a targeted ...

A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary ...

Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted ...

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that it received notice from the U.S. Food and Drug Administration’s Center ...

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the ...

Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia ® A novel non-antibiotic approach to diarrhea treatment is important because ...